目的 :探讨我国目前肝癌与非肝癌病人行肝移植治疗的风险及长期生存效果。方法 :回顾性总结2 1例晚期肝癌病人行肝移植手术治疗风险及长期生存情况 ,并与同期所行另外 19例非肝癌病人的肝移植进行比较。结果 :晚期肝癌病人的手术前凝血状态好于因其它非肝癌原因而接受肝移植的病人 ,与此相应的手术中出血量、需要输血量、术中输液总量均少于非肝癌病人 ,手术中因出血而导致的低血压时间短 ,手术后较恢复顺利 ,围手术期病死率低。虽然肿瘤复发所致的远期死亡率明显高于非肝癌病人 ,但是 ,总生存率与非肝癌病人无明显区别 ,部分病人可长期无瘤生存。结论 :现阶段肝移植仍是失去根治性切除机会的肝癌病人的有效治疗手段 ,术后部分病人有无瘤长期生存的可能性 Objective: To investigate the risk and long-term survival of hepatocellular carcinoma patients and non-hepatocellular carcinoma patients undergoing liver transplantation in our country. Methods: The risk and long-term survival of 21 patients with HCC undergoing liver transplantation were retrospectively reviewed. The results were compared with those of 19 patients with non-HCC who underwent liver transplantation in the same period. Results: The preoperative coagulation status of patients with advanced liver cancer was better than that of patients who underwent liver transplantation because of other causes of non-liver cancer. Corresponding intraoperative blood loss, transfusion volume and total intraoperative fluid infusion were less than those of non-liver cancer patients. Surgery Hypotension caused by bleeding in a short time after the operation was more successful, perioperative mortality was low. Although the long-term mortality due to tumor recurrence was significantly higher than non-liver cancer patients, however, there was no significant difference between the overall survival rate and non-liver cancer patients, some patients can be long-term tumor-free survival. Conclusion: Liver transplantation is still an effective treatment for patients with liver cancer who have lost their chances of radical resection at this stage, and some patients may have long-term survival after surgery